Clinical Trial

Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, single-arm, open-label clinical study of 177Lu-CTR-FAPI injection in the treatment of patients with advanced, metastatic solid tumors i.e. pancreatic cancer, to assess safety, radio-dosimetry, and efficacy per RESIST 1.1.
Trial Details
NCT Number NCT07229768
Lead Sponsor Yan Xing
Conditions Pancreatic Cancer
Enrollment 4 participants
Start Date 2025-10-15
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-17